Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Supernus Pharmaceuticals Inc. (SUPN)

21.46   0.62 (2.98%) 10-01 16:04
Open: 20.86 Pre. Close: 20.84
High: 21.6 Low: 20.82
Volume: 496,822 Market Cap: 1,130M
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 448 full-time employees. The firm offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). The company is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. The company is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The firm's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 21.185 - 21.286 21.286 - 21.38
Low: 20.293 - 20.409 20.409 - 20.517
Close: 20.652 - 20.832 20.832 - 21.001

Technical analysis

as of: 2020-10-01 3:39:40 PM
Overall:       
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 26.69     One year: 31.17
Support: Support1: 21.07    Support2: 19.97
Resistance: Resistance1: 22.85    Resistance2: 26.69
Pivot: 21.31
Moving Average: MA(5): 20.82     MA(20): 21.32
MA(100): 23.07     MA(250): 22.46
MACD: MACD(12,26): -0.42     Signal(9): -0.44
Stochastic oscillator: %K(14,3): 37.35     %D(3): 29.84
RSI: RSI(14): 48.98
52-week: High: 29.36  Low: 13.12  Change(%): -20.3
Average Vol(K): 3-Month: 45673  10-Days: 42104

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
SUPN has closed below upper band by 45.3%. Bollinger Bands are 17.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 01 Oct 2020
Brokerages Expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Will Announce Quarterly Sales of $131.35 Million - MarketBeat

Mon, 21 Sep 2020
Is Supernus Pharmaceuticals Inc (SUPN) a Stock to Watch This Week? - InvestorsObserver

Mon, 14 Sep 2020
Supernus Pharma (SUPN) Reports Submission of NDA for SPN-830 - StreetInsider.com

Wed, 09 Sep 2020
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference - Yahoo Finance

Wed, 19 Aug 2020
Supernus Pharmaceuticals Inc (SUPN) Q2 2020 Earnings Call Transcript - Motley Fool

Tue, 11 Aug 2020
Supernus Announces Preliminary Second Quarter 2020 Revenue Nasdaq:SUPN - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers General Specialty & Generic
Shares Out. (M) 53
Shares Float (M) 51
% Held by Insiders 3.43
% Held by Institutions 103.22
Shares Short (K) 5,400
Shares Short P. Month (K) 4,800

Stock Financials

EPS 2.200
EPS Est This Year 1.040
EPS Est Next Year 1.660
Book Value (p.s.) 12.650
Profit Margin 27.85
Operating Margin 37.78
Return on Assets (ttm) 7.8
Return on Equity (ttm) 19.9
Qtrly Rev. Growth 21.0
Gross Profit (p.s.) 7.142
Sales Per Share 8.057
EBITDA (p.s.) 3.203
Qtrly Earnings Growth 5.90
Operating Cash Flow (M) 182
Levered Free Cash Flow (M) 191

Stock Valuations

PE Ratio 9.75
PEG Ratio
Price to Book value 1.70
Price to Sales 2.66
Price to Cash Flow 6.20

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.